A New Hope: Dual Human Epidermal Growth Factor Receptor 2 Blockade and Chemotherapy in Human Epidermal Growth Factor
Wanfen Tang1, Hongjuan Zheng1, Qinghua Wang1
1Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Introduction:
Monoclonal antibodies targeting epidermal growth factor receptors (EGFRs) are currently the preferred targeted therapeutic agents for RAS wild-type, left-sided metastatic colorectal cancer (mCRC). Nonetheless, certain molecular alterations within mCRC confer resistance to anti-EGFR monoclonal antibody therapy, notably alterations involving human epidermal growth factor receptor 2 (HER2). Colorectal cancer (CRC) characterized by HER2 amplification or overexpression may have markedly different prognoses than HER2-negative CRC does. Recent clinical trials have demonstrated that dual HER2 blockade leads to significant improvements in clinical outcomes for these patients.
Case Presentation:
In this study, we present a case in which HER2-positive mCRC was successfully treated with HER2-targeted agents combined with chemotherapy, resulting in favorable clinical outcomes.
Conclusion:
Dual HER2-targeted therapy combined with chemotherapy is a promising strategy for HER2-positive mCRC patients with good performance status. This approach warrants validation in large-scale clinical trials to confirm its efficacy.
Insights
Dual HER2 blockade combined with chemotherapy shows promise for treating HER2-positive metastatic colorectal cancer (mCRC). This approach led to favorable outcomes in a recent case study, suggesting potential for broader clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Epidermal growth factor receptor (EGFR) inhibitors are standard for RAS wild-type metastatic colorectal cancer (mCRC).
- HER2 alterations (amplification/overexpression) in mCRC can cause resistance to anti-EGFR therapy.
- HER2-positive mCRC may have a distinct prognosis compared to HER2-negative disease.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers